GlassScriptPhysician profile
Alejandra Solis
NPI 1184030736
$2,085.37
in general payments reported to CMS, 2019-2025
23 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,004 · 2024: $825 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.19 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $467.63 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $231.35 | 2023-2024 | |
| Pfizer INC. | $126.18 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $85.54 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Mylan Specialty L.P. | $79.37 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $78.71 | 2023 | Mounjaro, Trulicity |
| Lundbeck LLC | $73.17 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $57.98 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $43.88 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.16 | 2023 | Tradjenta, Jardiance |
| Otsuka America Pharmaceutical, INC. | $36.00 | 2023-2024 | Rexulti |
| Daiichi Sankyo INC. | $22.70 | 2024 | Injectafer |
| Genentech USA, INC. | $21.23 | 2024 | Xolair |
| Viiv Healthcare Company | $20.82 | 2024 | Dovato |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.68 | 2024 | Caplyta |
| Hologic Sales and Service, LLC | $18.05 | 2024 | Thinprep 2000 Processor, Aptima |
| Corium, LLC | $16.91 | 2023 | Azstarys |
| Dexcom, INC. | $16.78 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $16.18 | 2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $15.95 | 2023 | |
| Organon LLC | $14.81 | 2024 | |
| Astellas Pharma US INC | $14.10 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.